Federal Judge Sends FDA's 2023 Abortion Pill Rules Back for Review, Calling Them 'Arbitrary and Capricious'
A U.S. district judge in Virginia found the FDA did not adequately justify certification and paperwork rules for mifepristone, but left those rules in force while the agency reconsiders them.
A Judge Ruled Against the FDA. Nothing Changed.
On July 24, 2026, a federal judge in Virginia found that the FDA broke the law when it set the current rules for the abortion pill mifepristone[2][3]. U.S. District Judge Robert S. Ballou called the rules "arbitrary and capricious"[1][2]. He wrote that the FDA "has steadfastly found, over the past quarter century, that mifepristone is a safe and effective medication"[1][2].
Here's the part most headlines left out. Ballou did not strike the rules down. He sent them back to the FDA to redo its work, and left every rule in force while that happens[1][6]. So the ruling and the rulebook point in opposite directions at once: a court says the FDA broke the law, and the law the FDA broke is still binding today.
That's not a contradiction. It's how this kind of case works. And understanding why takes explaining one piece of legal plumbing that decides everything about what this ruling actually does.
Why "Unlawful" Didn't Change Anything
When a judge finds an agency didn't properly justify a rule, the law gives two options. The judge can vacate the rule, erasing it immediately. Or the judge can remand it — send it back to the agency to explain itself better, while the rule stays on the books in the meantime[1][6].
Ballou chose remand, not vacatur. He set no deadline for the FDA to finish[1]. That means the rules at issue — doctors must register with the drug's maker, pharmacies must get certified and keep detailed records, and patients must sign a form describing the drug's risks — all remain in effect right now[1][2].
The Center for Reproductive Rights, which sued on behalf of abortion providers in Virginia, Kansas and Montana back in 2023, called the restrictions unjustified and baseless[2][5]. That's true as far as the court's reasoning goes. But it's a description of a legal finding, not a description of what a patient, doctor or pharmacist experiences differently today — because nothing is different today[1][6].
The Same 2023 Decision, Attacked From Both Sides
The rules Ballou reviewed came out of one FDA decision in 2023. That decision cut two ways at once. It loosened some things — allowing retail pharmacies to dispense mifepristone and ending a requirement that patients pick it up in person. But it kept other things — the certification and paperwork requirements now at issue in this case[13][16].
So the same 2023 action is being sued over from opposite directions. Abortion providers say the paperwork requirements that survived are unjustified and should go[15]. Louisiana and other states, in a separate case called Louisiana v. FDA, argue the loosening went too far and should be reversed[12]. The Supreme Court stepped into that fight on May 14, 2026, staying a lower court order and leaving mail delivery and telehealth prescribing in place while the case continues[12][13].
The government's own lawyers, from the Trump administration's Justice Department, defended the certification rules in Ballou's courtroom. Their argument: the paperwork is not an obstacle to safe use. It's the trade-off that let the FDA loosen distribution as much as it did in the first place[16]. Strip the conditions, and the agency loses the tool it used to justify the looser system.
A Number Both Sides Cite, Meaning Different Things
Underneath the legal fight sits a genuine dispute over how risky mifepristone actually is. The FDA's label says serious problems happen in fewer than 0.5% of patients, based on 10 clinical trials covering more than 30,000 people[10]. The Ethics and Public Policy Center, a conservative think tank, analyzed insurance claims covering 865,727 mifepristone abortions from 2017 to 2023. It reported a 10.93% serious adverse event rate — more than 20 times higher[8][9].
That gap looks like a math problem. It's actually a definitions problem. Clinical trials track a specific, narrow list of serious events in screened, monitored patients. The insurance-claims study counts a broader set of events, drawn from real-world billing codes rather than a controlled trial[8][10]. Critics at KFF and the Guttmacher Institute say the think tank's paper was never peer-reviewed and counts things the FDA wouldn't classify as serious[10][11].
Whichever definition wins out will do most of the work in deciding the final answer, before any new data gets analyzed. That's exactly the question now sitting in front of the FDA, which is running its own safety review separate from this lawsuit[14].
The Agency Now Redoing Its Homework Wants a Different Answer
Health and Human Services Secretary Robert F. Kennedy Jr. first ordered that safety review in September 2025, when Marty Makary was FDA Commissioner. Makary resigned in May 2026. Acting Commissioner Kyle Diamantas now oversees the review[14]. A separate court order requires a status report on it by October 7, 2026[17].
That timing matters more than it might seem. Ballou's ruling hands the FDA's reconsideration of these rules to the very agency already conducting a safety review under leadership that has publicly questioned mifepristone's safety[14]. A ruling that reads, on its face, as a win for the abortion providers who brought the case could end up accelerating a rewrite they don't want.
Pharmacies and prescribing doctors, meanwhile, are mostly not arguing about abortion at all. They're tracking compliance risk. A pharmacy chain has to know which of its stores are certified and keep records a state attorney general could subpoena[1][16]. A doctor who registers to prescribe the drug ends up on a list that, in states hostile to abortion, some see as a safety and licensing concern, not paperwork[5][20]. What this group wants most is a stable rule — any stable rule — and a remand with no deadline is close to the opposite of that[6].
How the Story Got Told
Coverage of the ruling split along familiar lines, though not always in obvious ways. Reuters and other wire services led with straight accounts of the holding, though even their language carried some framing — U.S. News' Reuters copy used the phrase "Biden-era restrictions," which is accurate but also quietly shifts responsibility away from the Trump administration lawyers who defended the same rules in court[3]. Agence France-Presse put "unlawful" in scare quotes and gave little space to the remand-without-vacatur detail, the fact most likely to leave international readers thinking the restrictions had actually been lifted[4].
Left-leaning outlets emphasized the strength of the judge's language. HuffPost's headline said the FDA "unjustly restricted" the pill, upgrading a technical finding about inadequate paperwork into a moral verdict the ruling itself didn't use[7]. Conservative outlets, for their part, largely skipped this specific ruling. Fox News' recent mifepristone coverage instead centered on the pending FDA safety review and its own deadline, treating this court loss as a footnote to a fight the right expects to win elsewhere[19].
Two advocacy groups did much of the shaping beneath that coverage. The Center for Reproductive Rights' press release, cited by multiple outlets, presented the ruling as vindication without foregrounding that its own clients remain bound by every rule it challenged[5]. The Ethics and Public Policy Center's report anchors the right's case that the FDA's official numbers understate the risk — a claim that rests on how broadly "serious adverse event" gets defined, not on a disagreement over the raw data[8][9][10].
What happens next isn't on any court's calendar. The FDA has to write a new justification for rules a judge just called unlawful, with no deadline forcing its hand[1]. Its safety review, due for a status update by October 7, 2026, sits in the same building[17]. Whichever answer the agency lands on will do more to change what a patient or doctor actually experiences than this ruling did.
Summary
On July 24, 2026, U.S. District Judge Robert S. Ballou ruled that the Food and Drug Administration broke federal law when it set 2023 rules on the abortion pill mifepristone[2][3]. Those rules require doctors to register with the drug's maker, require pharmacies to get certified and keep detailed records, and require patients to sign a form about the drug's risks[1][2]. Ballou wrote that the rules are "arbitrary and capricious" and that the FDA "has steadfastly found, over the past quarter century, that mifepristone is a safe and effective medication"[1][2]. He is a Biden appointee sitting in the Western District of Virginia[1].
Here is the part most headlines skipped. Ballou did not strike the rules down. He sent them back to the FDA to redo its analysis, and left them in force in the meantime[1][6]. Nothing changes today for a patient, a doctor, or a pharmacy. The Center for Reproductive Rights, which brought the case in 2023 for abortion providers in Virginia, Kansas and Montana, called the restrictions unjustified and baseless[5]. The FDA, defended in court by the Trump administration's Justice Department, argued the certification rules are what make the drug safe to distribute the way it is now distributed[16][20].
The real fight is over one question: how risky is mifepristone in ordinary use? The FDA's own label says serious problems happen in fewer than 0.5% of patients, based on 10 clinical trials covering more than 30,000 people[10]. The Ethics and Public Policy Center, a conservative Christian think tank, published an analysis of insurance claims for 865,727 mifepristone abortions from 2017 to 2023 and reported that 10.93% of women had a serious adverse event[8][9]. Critics at KFF and the Guttmacher Institute say that paper was never peer-reviewed and counts things the FDA would not count as serious[10][11]. The FDA is now running its own safety review, first ordered in September 2025 when Health and Human Services Secretary Robert F. Kennedy Jr. asked then-Commissioner Marty Makary to look at the data; Makary resigned in May 2026, and the review is now overseen by Acting FDA Commissioner Kyle Diamantas[14].
So the agency is being pushed hard from both sides at once. This Virginia ruling tells the FDA to justify the restrictions or drop them. In a separate case, Louisiana v. FDA, states are suing to make the rules tighter; the Supreme Court blocked a lower-court order on May 14, 2026 and left mail and telehealth access in place while that case goes on[12][13].
The Event
On July 24, 2026, Judge Robert S. Ballou of the U.S. District Court for the Western District of Virginia ruled in Whole Woman's Health Alliance v. FDA that the FDA's 2023 modification of the mifepristone Risk Evaluation and Mitigation Strategy was unlawful under the Administrative Procedure Act[1][6]. He wrote that "the 2023 REMS modification is unlawful and must be remanded to the FDA for review" and that "the REMS modifications are arbitrary and capricious"[1][2]. Ballou remanded the rules to the agency without vacating them, so the prescriber certification, pharmacy certification and patient agreement form requirements remain in effect[1][6]. He set no deadline for the FDA to finish its reconsideration[1].
Undisputed Facts
- The FDA approved mifepristone in 2000 and has repeatedly reaffirmed that it is safe and effective when used as directed[1][2].
- The 2023 rules at issue require prescribers to register with the manufacturer, require pharmacies to be certified and keep records, and require patients to sign a form acknowledging risks[1][2].
- Judge Robert S. Ballou, appointed by President Joe Biden, ruled on July 24, 2026 that the 2023 REMS modification was arbitrary and capricious[1][2].
- Ballou remanded the rules to the FDA rather than striking them down; they stay in effect during the agency's reconsideration[1][6].
- The Center for Reproductive Rights filed the case in 2023 on behalf of abortion providers in Virginia, Kansas and Montana[2][15].
- The Trump administration's Justice Department defended the restrictions in this case, arguing the current rules are what keep the drug's distribution safe[16][20].
- The FDA is separately conducting a safety review of mifepristone, first requested by HHS Secretary Robert F. Kennedy Jr. in September 2025 when Marty Makary was FDA Commissioner; Makary resigned in May 2026, and the review is now overseen by Acting Commissioner Kyle Diamantas[14].
- On May 14, 2026, the Supreme Court blocked a Fifth Circuit order in Louisiana v. FDA, leaving telehealth prescribing and mail dispensing in place while that separate case continues[12][13].
The Pressure
Strip away the moralizing and blame. What structural realities persist regardless of which narrative wins?
- Remand without vacatur is the whole story
- Under the Administrative Procedure Act, a judge who finds an agency did not explain itself has two options. He can vacate the rule — erase it — or remand it, which means sending it back to the agency to redo the analysis while the rule stays in force. Ballou chose remand[1][6]. So a headline saying restrictions were 'ruled unlawful' and a reality in which every restriction is still binding are both accurate at the same time. This is the single fact most likely to be lost in coverage on either side.
- The agency being ordered to reconsider wants to reconsider — in the other direction
- The FDA is already running a mifepristone safety review, requested by HHS Secretary Robert F. Kennedy Jr.[14]. A court ordering that same agency to take a fresh look hands the redo to leadership that has publicly questioned the drug's safety. A ruling that reads as a win for abortion-rights plaintiffs may in practice accelerate a rewrite they do not want.
- Two lawsuits, one 2023 action, opposite directions
- The 2023 REMS modification both loosened access — allowing retail pharmacy dispensing and ending the in-person requirement — and kept certification and paperwork conditions[13][16]. Abortion providers are suing over the conditions that remain. Louisiana and allied states are suing over the loosening[12]. The same FDA decision is being called unlawful by both sides, for opposite reasons.
- The numbers fight is a definitions fight
- The gap between 'under 0.5%' and '10.93%' is not mainly about arithmetic[8][10]. It is about what counts as a serious adverse event, and about whether screened clinical-trial patients or real-world insurance claims better describe an ordinary patient. Whichever definition the FDA adopts in its review will largely determine the answer before any data is analyzed.
Material realityMifepristone is the drug used in the most common method of ending a pregnancy in the United States[20]. As of today, July 27, 2026, its rules are unchanged: prescribers must still register with the manufacturer, pharmacies must still be certified and keep records, and patients must still sign the agreement form[1][6]. Telehealth prescribing and mail delivery remain legal nationwide because the Supreme Court stayed a contrary order on May 14, 2026[12][13]. Two federal deadlines now sit ahead of everything else — the FDA's status report on its safety review, due no later than October 7, 2026 under a separate April 2026 order[17], and the open-ended reconsideration Ballou just ordered with no deadline attached[1]. Whatever the FDA writes in that review will matter more to actual access than this ruling does, because the agency, not the district court, is the body that sets the rule.
Narrative as a weaponTwo well-funded advocacy operations are doing most of the shaping here, and both are working around thin news coverage rather than through it. The Center for Reproductive Rights is a party to the case; its press release is the source many outlets summarized, and it wants readers to believe a court declared the restrictions baseless — true as to the holding, misleading as to the effect, since nothing was lifted. The Ethics and Public Policy Center wants readers to believe the official safety record is an artifact of the FDA's decision in 2016 to stop collecting most non-fatal adverse event reports, and that its own claims-database figure is the truer number; its analysis is self-published, not peer-reviewed, and uses a broader definition of harm than the FDA's, which critics at KFF and Guttmacher say inflates the rate. The Trump administration is the quietest actor and possibly the most consequential: its Justice Department defended rules written under Biden, while its HHS leadership runs a review that could replace them. Wire coverage from Reuters and AFP is the most restrained, but even there the headline verb — 'blocks,' 'rules unlawful' — overstates what changed on the ground, which is nothing.
How Each Side Sees It
Each major actor’s view — how it frames things, its underlying incentive, and how it’s materially affected. Tap a side to read it.
Frames it asTheir case is not really about abortion politics — it is about whether an agency has to follow its own rules. Congress said the FDA may add extra safety conditions to a drug only when it finds those conditions are needed, and only if they are not unduly burdensome[15]. Providers say the FDA never made that finding for mifepristone in 2023 and never engaged with evidence that the paperwork does not make anyone safer[15]. Their second argument is practical: certification is not a small chore. A rural family doctor who prescribes the drug twice a year must register with a manufacturer and be listed in its records, and a small pharmacy must build a separate recordkeeping system. Many simply do not bother, so the burden falls on the patient who then has to drive further or wait longer[5][20]. Their third argument is consistency: no other drug with mifepristone's safety record carries this kind of gatekeeping[5].
WhyThey want the REMS gone entirely, so that mifepristone can be prescribed like an ordinary prescription drug and access does not depend on how many local providers are willing to do the paperwork[5][15]. A published finding that the FDA acted unlawfully is also a durable legal asset they can cite in the other mifepristone cases[6].
Impact on themThey won the legal holding but not the relief. Because Ballou remanded without vacating, no provider or pharmacy is freed from any requirement today[1][6]. The ruling also hands the FDA's reconsideration to an administration whose HHS leadership has publicly questioned the drug's safety, which means the redo could end with the same rules — or tighter ones[14].
Frames it asThe government's position in court was that the certification requirements are not obstacles to safe use — they are the reason the current, looser distribution system is defensible at all. The 2023 action is what let retail pharmacies dispense mifepristone and ended the in-person dispensing requirement; certification and recordkeeping were the trade[13][16]. Strip the conditions and the agency loses the tool that made the loosening possible in the first place[16]. A second argument is institutional: under the Administrative Procedure Act, a judge reviews whether an agency explained itself, not whether the judge would have chosen the same rule. Scientific line-drawing on drug risk is the FDA's job, and a court that second-guesses it substitutes its own judgment for the expert agency's[16]. Third, the agency says the honest answer is "wait": it has an active safety review underway and has asked courts to hold mifepristone cases until that review is done[1][14].
WhyThe administration is cross-pressured. Its own FDA is defending Biden-era rules it did not write, while its HHS secretary has ordered a fresh safety review that anti-abortion allies expect to justify tighter rules[14]. Defending the status quo in court preserves the agency's authority to set drug conditions — authority a future tightening would also need[16].
Impact on themThe FDA now owes a new, better-documented explanation with no court-set deadline[1]. Whatever it writes will be read in at least two other courtrooms. A separate April 7, 2026 ruling requires a status report on the safety review by October 7, 2026[17]. Politically, any outcome angers someone: keep the rules and the ruling stands unanswered; loosen them and the administration's base revolts; tighten them and it invites a fresh round of litigation.
Frames it asTheir core claim is that the official safety numbers come from a system built to miss the harm. In 2016 the FDA stopped requiring providers to report non-fatal adverse events from mifepristone, so, they argue, the agency's own data cannot show what it claims to show[8][9]. That is why they point to insurance claims instead: the Ethics and Public Policy Center analyzed 865,727 mifepristone abortions from 2017 to 2023 and reported that 10.93% of women had sepsis, infection, hemorrhage or another serious event — a rate they say is at least 22 times the label's figure[8][9]. Their second argument is about who bears the risk. Clinical trials enroll screened, monitored patients near a hospital. A woman who orders pills online and takes them alone at home is not that patient, and the REMS paperwork is one of the few remaining points where a clinician has to be involved[18]. Third, they argue the courts are being used to dismantle drug safeguards that Congress gave the FDA discretion to set — and that a single district judge should not be the one making that call[18].
WhyThe immediate goal is not this ruling but the FDA's safety review, which they see as the fastest route to restoring in-person dispensing and ending mail-order access nationwide without needing Congress[14][19]. Some groups have publicly pressed the administration to move faster on it[19].
Impact on themA remand without vacatur costs them nothing right now — the restrictions they want kept are still in force[6]. But the ruling creates a written judicial finding that the FDA's justification was inadequate, which future courts can cite. Their bigger vehicle remains Louisiana v. FDA, where the Supreme Court's May 14, 2026 stay left mail and telehealth access intact for now[12][13].
Frames it asThis group is mostly not arguing about abortion. It is arguing about compliance risk. Certification means a pharmacy chain must track which stores are certified, keep the records the REMS requires, and absorb the legal exposure if a state attorney general subpoenas them[1][16]. Clinicians say registering with a manufacturer creates a searchable list of who prescribes the drug, which in states hostile to abortion is a personal safety and licensing concern, not just paperwork[5][20]. Both want a clear, stable rule more than they want any particular rule. Repeated flips — the 2023 change, the Fifth Circuit stay, the Supreme Court stay, now this remand — make it hard to decide whether to stock the drug at all[13].
WhyPredictability and liability limits. A remand with no deadline is close to the worst case for planning, because the rule they are complying with has now been declared unlawful but is still binding[6].
Impact on themNo operational change today. But mifepristone is used in the most common method of ending a pregnancy in the U.S.[20], so any final FDA decision — looser or tighter — reshapes which pharmacies stock it, which clinicians prescribe it, and how the two generic and brand manufacturers distribute it[13].
Like this article?
The Bias Ledger average rating 5.1
The same story, as framed by outlets across the spectrum, ordered least to most biased. The bias score (1 = straight, 10 = heavily spun) is an AI assessment of that framing — click an outlet to see its track record. The tell is the word choice or omission that reveals the angle.
| Outlet | Vantage | Bias | How they frame it | The tell |
|---|---|---|---|---|
| Reuters | U.S./international wire, center | 3 | "US judge says Biden-era restrictions on prescribing abortion drug are unlawful" — straight account of the holding, with the judge's reasoning quoted. | "Biden-era" is accurate but does quiet political work: it assigns the rules to the previous administration, softening the fact that the current administration's Justice Department defended them. The URL slug says the judge "blocks" the restrictions, which he explicitly did not do. |
| Agence France-Presse | French wire, international centrist | 3 | "US court rules abortion pill restrictions 'unlawful'" — a U.S. court checking the Trump administration. | Scare quotes around 'unlawful' signal distance from the finding. The remedy — remand, not vacatur — is compressed, so a reader can finish the piece thinking restrictions were lifted. |
| Stateline | U.S. left-of-center nonprofit newsroom (States Newsroom, funded largely by progressive donors) | 4 | "Federal judge says certain abortion drug restrictions are unlawful" — careful hedge on 'certain,' and it does report that the rules were not struck down. | Sources the ruling's reasoning fully but gives little space to the government's actual legal argument that certification is the trade-off enabling pharmacy dispensing. The anti-abortion evidence appears mainly as 'a study by a conservative think tank that never underwent formal peer review.' |
| Fox News | U.S. right | 4 | No Fox news story on the Ballou ruling surfaced in this search set. Its recent mifepristone framing centers on the Supreme Court leaving the pill available by mail while 'FDA faces 6-month review deadline.' | The framing device is the clock, not the court: the story is the pending FDA safety review that could tighten the rules, with adverse court outcomes treated as temporary. Note this ledger entry rates an adjacent story, not this ruling. |
| HuffPost | U.S. left | 6 | "Federal Judge Rules FDA Unjustly Restricted Abortion Pill Mifepristone" — a wrong done to patients, now named by a court. | 'Unjustly' upgrades a technical administrative-law finding (inadequate explanation) into a moral verdict. The word 'unjust' appears nowhere in the quoted holding. |
| Center for Reproductive Rights | U.S. left legal advocacy group — and a party to this case | 8 | "Federal Court Rules FDA Abortion Pill Restrictions Are Unjustified" — the court says the FDA ignored the scientific record. | This is a litigant's press release, not journalism. It leads with the strongest words in the opinion and does not foreground that the restrictions it sued over are all still binding on its own clients. |
| Ethics and Public Policy Center | U.S. right, religious-conservative think tank — the source of the 10.93% figure and an amicus for Louisiana | 8 | "The Abortion Pill Harms Women: Insurance Data Reveals One in Ten Patients Experiences a Serious Adverse Event." | The headline states the conclusion the analysis is meant to support. The paper is self-published and not peer-reviewed, and its definition of 'serious adverse event' is broader than the FDA's — a methodological choice that drives the whole gap between 10.93% and 0.5%. |
References
- Federal judge in Virginia says certain abortion drug restrictions are unlawful — WTOP News · Washington, D.C. commercial news radio; carrying reporting from States Newsroom's Stateline, a left-of-center nonprofit newsroom
- Federal judge says certain abortion drug restrictions are unlawful — Stateline · U.S. left-of-center nonprofit newsroom, part of States Newsroom, funded largely by progressive foundations and donors
- US Judge Says Biden-Era Restrictions on Prescribing Abortion Drug Are Unlawful — Reuters · International wire service, center; owned by Thomson Reuters
- US court rules abortion pill restrictions 'unlawful' — Agence France-Presse · French wire service, partially state-funded through a public-interest contract with the French government; international centrist
- Federal Court Rules FDA Abortion Pill Restrictions Are Unjustified — Center for Reproductive Rights · U.S. abortion-rights legal advocacy nonprofit; plaintiffs' counsel in this case, so an interested party rather than an observer
- District Court: Restrictions On Mifepristone Illegal But Will Remain In Effect Pending FDA Reconsideration — Health Affairs Forefront · Peer-reviewed U.S. health policy journal published by Project HOPE; academic, generally establishment health-policy in orientation
- Federal Judge Rules FDA Unjustly Restricted Abortion Pill Mifepristone — HuffPost · U.S. left, owned by BuzzFeed Inc.
- The Abortion Pill Harms Women: Insurance Data Reveals One in Ten Patients Experiences a Serious Adverse Event — Ethics and Public Policy Center · U.S. conservative, religiously-grounded think tank; explicitly anti-abortion advocacy; self-published, not peer-reviewed
- The Abortion Pill Harms Women (full report PDF) — Ethics and Public Policy Center · U.S. conservative anti-abortion think tank; the underlying document for the 10.93% figure
- Flawed Report Aims to Undercut Established Research on Abortion Pill Safety — KFF · U.S. health policy research organization, formerly the Kaiser Family Foundation; independent of Kaiser Permanente, generally establishment public-health in orientation
- The War on Mifepristone: How Junk Science and False Narratives Threaten US Abortion Access — Guttmacher Institute · U.S. reproductive-health research and policy organization; originally founded within Planned Parenthood, openly supports abortion access
- Louisiana v. FDA: Access to Mifepristone Back at the Supreme Court — KFF · U.S. health policy research organization; establishment public-health orientation
- Supreme Court Stays Fifth Circuit Order Banning Telehealth Prescribing and Mail Dispensing of Mifepristone — Goodwin Procter · Corporate law firm client alert; written for pharmaceutical and life-sciences clients, not politically aligned but industry-facing
- FDA to conduct safety review of abortion pill mifepristone — The Hill · U.S. centrist political trade publication; owned by Nexstar Media Group
- Whole Woman's Health Alliance v. FDA (case page) — Center for Reproductive Rights · Plaintiffs' counsel in the case; abortion-rights legal advocacy nonprofit
- Defendants' Combined Memorandum in Support of Cross-Motion for Summary Judgment (Whole Woman's Health Alliance v. FDA) — U.S. Department of Justice court filing, via Georgetown Health Care Litigation Tracker · Primary source — the federal government's own legal brief defending the REMS; hosted by a Georgetown Law academic tracker
- The Latest on Medication Abortion Access: The Court Awaits the FDA Review — KFF · U.S. health policy research organization; establishment public-health orientation
- Brief of Amicus Curiae Ethics and Public Policy Center in Support of Louisiana (Nos. 25A1207, 25A1208) — Supreme Court of the United States (docket) · Primary source — filing by a conservative anti-abortion think tank, hosted on the Court's official docket
- Abortion pill mifepristone stays available by mail as FDA faces 6-month review deadline — Fox News · U.S. right; owned by Fox Corporation
- Abortion providers challenge FDA's remaining mifepristone restrictions in federal court — Virginia Mercury · U.S. left-of-center nonprofit state newsroom, part of States Newsroom
- Whole Woman's Health Alliance et al. v. U.S. Food and Drug Administration et al. (docket tracker) — Georgetown Health Care Litigation Tracker · Academic litigation database at Georgetown Law's O'Neill Institute; document repository rather than commentary